Ignite Creation Date:
2024-05-06 @ 11:05 AM
Last Modification Date:
2024-10-26 @ 12:39 PM
Study NCT ID:
NCT03420742
Status:
COMPLETED
Last Update Posted:
2023-01-27
First Post:
2018-01-29
Brief Title:
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Participants With ALK-Positive or ROS1-Positive Solid Tumors
Sponsor:
Takeda
Organization:
Takeda
Organization Data
Organization:
Takeda
Class:
INDUSTRY
Study ID:
Brigatinib-1001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Takeda
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None